To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.

Lead sponsor: UCB Pharma•43 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETEDPhase 3

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655486 · Partial Epilepsies, Partial Onset Seizures

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 17, 2018Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment370

Start dateAug 2001

Last updatedJul 17, 2018

Condition

Partial Epilepsies

Locations shown

Birmingham, Alabama

Huntsville, Alabama

Phoenix, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 17, 2018Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions